2022 SIAIP共识:5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理

2022-05-16 意大利儿童变态反应和免疫学会 Ital J Pediatr

2022年5月,意大利儿童变态反应和免疫学会(SIAIP)针对5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理提供指导建议。BNT162b2 mRNA C

中文标题:

2022 SIAIP共识:5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理

英文标题:

Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

发布日期:

2022-05-16

简要介绍:

2022年5月,意大利儿童变态反应和免疫学会(SIAIP)针对5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理提供指导建议。BNT162b2 mRNA COVID-19疫苗被批准用于5-11岁儿童,最新的数据显示疫苗的安全性,报告的严重不了事件很少。本文主要针对5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理提供指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2022 SIAIP共识:5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=8133a1c002a41198, title=2022 SIAIP共识:5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理, enTitle=Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP), guiderFrom=Ital J Pediatr, authorId=0, author=, summary=2022年5月,意大利儿童变态反应和免疫学会(SIAIP)针对5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理提供指导建议。BNT162b2 mRNA C, cover=https://img.medsci.cn/20220518/1652874336186_1608702.jpg, journalId=0, articlesId=null, associationId=1390, associationName=意大利儿童变态反应和免疫学会, associationIntro=, copyright=0, guiderPublishedTime=Mon May 16 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">2022年5月,意大利儿童变态反应和免疫学会(SIAIP)针对5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理提供指导建议。BNT162b2 mRNA COVID-19疫苗被批准用于5-11岁儿童,最新的数据显示疫苗的安全性,报告的严重不了事件很少。本文主要针对5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理提供指导建议。</span></p>, tagList=[TagDto(tagId=438104, tagName=BNT162b2 mRNA COVID-19疫苗)], categoryList=[CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=18, categoryName=儿科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3588, appHits=56, showAppHits=0, pcHits=124, showPcHits=3529, likes=2, shares=14, comments=3, approvalStatus=1, publishedTime=Thu May 19 15:43:00 CST 2022, publishedTimeString=2022-05-16, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Wed May 18 19:49:08 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sun Dec 24 15:08:36 CST 2023, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2022 SIAIP共识:5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理.pdf)])
2022 SIAIP共识:5-11岁伴过敏、哮喘和免疫缺陷儿童接种BNT162b2 mRNA COVID-19疫苗的管理.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1221263, encodeId=631f1221263b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Fri May 20 19:46:57 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221118, encodeId=3a941221118ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230213/5855e9a7e85e4b808849362164402c52/25868520bd3e4851a7619202ec8728e2.jpg, createdBy=357c6553867, createdName=ms3000001005882169, createdTime=Fri May 20 10:35:50 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
    2022-05-20 清漩

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1221263, encodeId=631f1221263b5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1bdd5596550, createdName=清漩, createdTime=Fri May 20 19:46:57 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221118, encodeId=3a941221118ff, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230213/5855e9a7e85e4b808849362164402c52/25868520bd3e4851a7619202ec8728e2.jpg, createdBy=357c6553867, createdName=ms3000001005882169, createdTime=Fri May 20 10:35:50 CST 2022, time=2022-05-20, status=1, ipAttribution=)]
    2022-05-20 ms3000001005882169

    学习了

    0